Ass. Prof. Dr. Hoang Thi Diem Tuyet – Director of Hung Vuong Hospital said: “As a leading obstetrics and gynecology hospital in Ho Chi Minh City and the southern provinces, Hung Vuong Hospital works tirelessly to strengthen health workforce capacity, ensuring consistently high quality of women healthcare services and better patient outcomes. Through the strategic partnership with Bayer Vietnam, we can further leverage our strengths and expertise to address the diverse health-related needs of women and the community in general.”

Specifically, there will be series of scientific symposiums, educational programs and medical bulletins co-developed for healthcare professionals from Hung Vuong Hospital and its satellite hospitals as well as hospitals nationwide to keep them well updated with latest research and innovations on women's contraceptive options, effective treatment for endometriosis (a disease in which tissue similar to the lining of the uterus grows outside the uterus), heavy menstrual bleeding as well as nutritional needs during pregnancy.

Additionally, both parties are committed to investing efforts in sustaining their existing community initiatives including the Contraception Counseling Program for women of reproductive age; Health Counseling Program for women living with endometriosis; the Reproductive Healthcare Call Center 1900.6425 to continuously provide accurate and reliable medical information for Vietnamese women, empowering them to make their own informed health decisions.

Mr. Ingo Brandenburg - General Director of Bayer Vietnam, said: “At Bayer, we have the fundamental belief that empowering girls & women and providing them with access to quality healthcare are cornerstone of sustainable development. We greatly appreciate the cooperation with Hung Vuong Hospital and trust that this will enable both of us to extend our reach and impact on transforming women’s health for a better and healthier world, contributing to a future of “Health for all, Hunger for none”. 

Recognized as a leader with strong heritage and deeply rooted expertise in women’s healthcare, Bayer offers a broad portfolio of effective medicines and health solutions for women at every different stage of life, including short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide. 

Globally, Bayer has pledged its commitment until 2030 to providing 100 million women, especially women in low- and middle-income countries, with access to modern contraception to make informed choices by funding multi-stakeholder aid programs and ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the United Nations Sustainable Development Goals.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.